Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 69 articles:
HTML format
Text format



Single Articles


    July 2017
  1. DETTI B, D'Angelillo RM, Ingrosso G, Olmetto E, et al
    Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy.
    Anticancer Res. 2017;37:3717-3722.
    PubMed     Text format     Abstract available


  2. MIYAZAWA Y, Takahiro S, Yoshitaka S, Nomura M, et al
    Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
    Anticancer Res. 2017;37:3667-3671.
    PubMed     Text format     Abstract available


  3. OZGUR E, Celik AI, Darendeliler E, Gezer U, et al
    PCA3 Silencing Sensitizes Prostate Cancer Cells to Enzalutamide-mediated Androgen Receptor Blockade.
    Anticancer Res. 2017;37:3631-3637.
    PubMed     Text format     Abstract available


  4. WINTERS B, Brown L, Coleman I, Nguyen H, et al
    Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
    Anticancer Res. 2017;37:3385-3396.
    PubMed     Text format     Abstract available


    June 2017
  5. HU JC, Hung SC, Ou YC
    Assessments of Neoadjuvant Hormone Therapy Followed by Robotic-Assisted Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer.
    Anticancer Res. 2017;37:3143-3150.
    PubMed     Text format     Abstract available


  6. HONDA M, Yogosawa S, Kamada M, Kamata Y, et al
    A Novel Near-infrared Fluorescent Protein, iRFP720, Facilitates Transcriptional Profiling of Prostate Cancer Bone Metastasis in Mice.
    Anticancer Res. 2017;37:3009-3013.
    PubMed     Text format     Abstract available


  7. FITZPATRICK C, Lynch O, Marignol L
    68Ga-PSMA-PET/CT Has a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease.
    Anticancer Res. 2017;37:2753-2760.
    PubMed     Text format     Abstract available


    April 2017
  8. JOHANSSON AK, Lennernas B, Isacsson U
    Neurovascular Bundle Infiltration Can Explain Local Relapses Using Conformal Radiotherapy of Prostate Cancer.
    Anticancer Res. 2017;37:1825-1830.
    PubMed     Text format     Abstract available


  9. PARK J, Joung JY, Hwang JE, Hong D, et al
    Ninjurin1 Is Up-regulated in Circulating Prostate Tumor Cells and Plays a Critical Role in Prostate Cancer Cell Motility.
    Anticancer Res. 2017;37:1687-1696.
    PubMed     Text format     Abstract available


  10. MABUCHI M, Ueda M, Yoshida Y, Horiike K, et al
    Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.
    Anticancer Res. 2017;37:1665-1676.
    PubMed     Text format     Abstract available


  11. OU YC, Hung SC, Hwang LH, Yang CK, et al
    Salvage Robotic-assisted Laparoscopic Radical Prostatectomy: Experience with 14 Cases.
    Anticancer Res. 2017;37:2045-2050.
    PubMed     Text format     Abstract available


    March 2017
  12. CICERO G, DE Luca R, Dorangricchia P, Dieli F, et al
    The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
    Anticancer Res. 2017;37:1475-1480.
    PubMed     Text format     Abstract available


  13. PALUMBO I, Matrone F, Montesi G, Bellavita R, et al
    Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study.
    Anticancer Res. 2017;37:1453-1457.
    PubMed     Text format     Abstract available


  14. HENKENBERENS C, VON Klot CA, Ross TL, Bengel FM, et al
    68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy.
    Anticancer Res. 2017;37:1273-1279.
    PubMed     Text format     Abstract available


  15. SCIALPI M, Prosperi E, D'Andrea A, Martorana E, et al
    Biparametric versus Multiparametric MRI with Non-endorectal Coil at 3T in the Detection and Localization of Prostate Cancer.
    Anticancer Res. 2017;37:1263-1271.
    PubMed     Text format     Abstract available


  16. ELLIS-CALEO T, Hegde JV, Bath S, Mesko S, et al
    Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer.
    Anticancer Res. 2017;37:1237-1242.
    PubMed     Text format     Abstract available


  17. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


    February 2017
  18. MESSINA CS, Weiher H, Schmidt-Wolf IG
    Targeting Prostate Cancer with a Combination of WNT Inhibitors and a Bi-functional Peptide.
    Anticancer Res. 2017;37:555-559.
    PubMed     Text format     Abstract available


  19. LERTSUWAN K, Peters W, Johnson L, Lertsuwan J, et al
    Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells.
    Anticancer Res. 2017;37:529-537.
    PubMed     Text format     Abstract available


  20. ABLIN RJ, Owen S, Jiang WG
    Prostate Transglutaminase (TGase-4) Induces Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells.
    Anticancer Res. 2017;37:481-487.
    PubMed     Text format     Abstract available


  21. FANDELLA A, Scattoni V, Galosi A, Pepe P, et al
    Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights.
    Anticancer Res. 2017;37:413-424.
    PubMed     Text format     Abstract available


    January 2017
  22. DONDOO TO, Fukumori T, Daizumoto K, Fukawa T, et al
    Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Anticancer Res. 2017;37:125-134.
    PubMed     Text format     Abstract available


    December 2016
  23. YAMAGUCHI H, Hori M, Suzuki O, Seo Y, et al
    Clinical Significance of the Apparent Diffusion Coefficient Ratio in Prostate Cancer Treatment with Intensity-modulated Radiotherapy.
    Anticancer Res. 2016;36:6551-6556.
    PubMed     Text format     Abstract available


  24. THELLENBERG-KARLSSON C, Nyman C, Nilsson S, Blom R, et al
    Bone-targeted Novel Cytotoxic Polybisphosphonate Conjugate in Castration-resistant Prostate Cancer: A Multicenter Phase 1 Study.
    Anticancer Res. 2016;36:6499-6504.
    PubMed     Text format     Abstract available


  25. STRANDBERG S, Karlsson CT, Ogren M, Axelsson J, et al
    11C-Acetate-PET/CT Compared to 99mTc-HDP Bone Scintigraphy in Primary Staging of High-risk Prostate Cancer.
    Anticancer Res. 2016;36:6475-6479.
    PubMed     Text format     Abstract available


  26. JOENSUU T, Joensuu G, Kairemo K, Kiljunen T, et al
    Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation.
    Anticancer Res. 2016;36:6439-6447.
    PubMed     Text format     Abstract available


  27. TSAI PH, Cheng CH, Lin CY, Huang YT, et al
    Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells.
    Anticancer Res. 2016;36:6367-6380.
    PubMed     Text format     Abstract available


    November 2016
  28. KATO H, Furuya Y, Miyazawa Y, Miyao T, et al
    Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:6141-6149.
    PubMed     Text format     Abstract available


  29. KIM SH, Kim KY, Yu SN, Park SG, et al
    Monensin Induces PC-3 Prostate Cancer Cell Apoptosis via ROS Production and Ca2+ Homeostasis Disruption.
    Anticancer Res. 2016;36:5835-5843.
    PubMed     Text format     Abstract available


  30. LAO L, Shen J, Tian H, Yao Q, et al
    Secreted Phosphoprotein 24 kD Inhibits Growth of Human Prostate Cancer Cells Stimulated by BMP-2.
    Anticancer Res. 2016;36:5773-5780.
    PubMed     Text format     Abstract available


  31. BURONI FE, Persico MG, Pasi F, Lodola L, et al
    Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:5719-5730.
    PubMed     Text format     Abstract available


    October 2016
  32. CHELLURI R, Caza T, Woodford MR, Reeder JE, et al
    Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models.
    Anticancer Res. 2016;36:5079-5086.
    PubMed     Text format     Abstract available


    September 2016
  33. OU YC, Weng WC, Chang KS, Mei CE, et al
    Prophylactic Robotic-assisted Laparoscopic Radical Prostatectomy for Preoperative Suspicion of Prostate Cancer: Experience with 55 Cases.
    Anticancer Res. 2016;36:4895-901.
    PubMed     Text format     Abstract available


  34. KULDA V, Topolcan O, Kucera R, Kripnerova M, et al
    Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Anticancer Res. 2016;36:4787-93.
    PubMed     Text format     Abstract available


  35. SMITH AD, Truong M, Bristow R, Yip P, et al
    The Utility of Serum CA9 for Prognostication in Prostate Cancer.
    Anticancer Res. 2016;36:4489-92.
    PubMed     Text format     Abstract available


  36. PORPIGLIA F, DE Luca S, Passera R, Manfredi M, et al
    Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score.
    Anticancer Res. 2016;36:4833-9.
    PubMed     Text format     Abstract available


  37. SHIDA Y, Hakariya T, Takehara K, Onita T, et al
    Comparison Between a Combined Transrectal and Transperineal Approach and a Transrectal Approach for Prostate Rebiopsy.
    Anticancer Res. 2016;36:4685-90.
    PubMed     Text format     Abstract available


    August 2016
  38. ZUGOR V, Kuhn R, Engelhard K, Poth S, et al
    The Value of Endorectal Magnetic Resonance Imaging of the Prostate in Improving the Detection of Anterior Prostate Cancer.
    Anticancer Res. 2016;36:4279-83.
    PubMed     Text format     Abstract available


  39. SINHA AA, Pomroy FE Jr, Wilson MJ
    Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:3847-54.
    PubMed     Text format     Abstract available


  40. KADONO Y, Nohara T, Kadomoto S, Nakashima K, et al
    Investigating Urinary Conditions Prior to Robot-assisted Radical Prostatectomy in Search of a Desirable Method for Evaluating Post-prostatectomy Incontinence.
    Anticancer Res. 2016;36:4293-8.
    PubMed     Text format     Abstract available


  41. ZUGOR V, Poth S, Kuhn R, Bernat MM, et al
    Is an Extended Prostate Biopsy Scheme Associated with an Improvement in the Accuracy Between the Biopsy Gleason Score and Radical Prostatectomy Pathology? A Multivariate Analysis.
    Anticancer Res. 2016;36:4285-8.
    PubMed     Text format     Abstract available


  42. DI PIERRO GB, Grande P, Mordasini L, Danuser H, et al
    Safety and Efficacy of Robot-assisted Radical Prostatectomy in a Low-volume Center: A 6-year Single-surgeon Experience.
    Anticancer Res. 2016;36:4201-7.
    PubMed     Text format     Abstract available


    July 2016
  43. SAKAUE M, Maeda K, Ohno S, Ito T, et al
    Screening for Identification of Personalized Food to Promote Adiponectin Secretion in Patients with Cancer.
    Anticancer Res. 2016;36:3673-7.
    PubMed     Text format     Abstract available


  44. KARIHTALA P, Rissanen T, Tuominen H
    Male Malignant Phyllodes Breast Tumor After Prophylactic Breast Radiotherapy and Bicalutamide Treatment: A Case Report.
    Anticancer Res. 2016;36:3433-6.
    PubMed     Text format     Abstract available


    June 2016
  45. ONISHI T, Shibahara T, Masui S, Sugino Y, et al
    Efficacy of Ethinylestradiol Re-challenge for Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:2999-3004.
    PubMed     Text format     Abstract available


  46. GRISANTI S, Antonelli A, Buglione M, Almici C, et al
    Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature.
    Anticancer Res. 2016;36:2975-81.
    PubMed     Text format     Abstract available


  47. MAKI S, Itoh Y, Kubota S, Okada T, et al
    Late Rectal Toxicity from Image-guided Intensity Modulated Radiotherapy for Prostate Cancer.
    Anticancer Res. 2016;36:2967-73.
    PubMed     Text format     Abstract available


    May 2016
  48. KANEMOTO A, Matsumoto Y, Sugita T, Abe E, et al
    Risk Factors and Time to Occurrence of Genitourinary Toxicity After External Beam Radiotherapy for Prostate Cancer.
    Anticancer Res. 2016;36:2441-4.
    PubMed     Text format     Abstract available


    April 2016
  49. CAPOUN O, Mikulova V, Jancikova M, Honova H, et al
    Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest(R) System for Detection of Circulating Tumor Cells.
    Anticancer Res. 2016;36:2019-26.
    PubMed     Text format     Abstract available


  50. DAVIES RS, Smith C, Lester JF
    Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
    Anticancer Res. 2016;36:1799-803.
    PubMed     Text format     Abstract available


  51. OU YC, Yang CK, Chang KS, Wang J, et al
    Prevention and Management of Complications During Robotic-assisted Laparoscopic Radical Prostatectomy Following Comprehensive Planning: A Large Series Involving a Single Surgeon.
    Anticancer Res. 2016;36:1991-8.
    PubMed     Text format     Abstract available


  52. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Anticancer Res. 2016;36:1973-8.
    PubMed     Text format     Abstract available


    March 2016
  53. CUI YX, Evans BA, Jiang WG
    New Roles of Osteocytes in Proliferation, Migration and Invasion of Breast and Prostate Cancer Cells.
    Anticancer Res. 2016;36:1193-201.
    PubMed     Text format     Abstract available


  54. FRAGNI M, Bonini SA, Stabile A, Bodei S, et al
    Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells.
    Anticancer Res. 2016;36:913-20.
    PubMed     Text format     Abstract available


  55. WEEKS HP, Sanders AJ, Kynaston HG, Jiang WG, et al
    The Association Between WAVE1 and -3 and the ARP2/3 Complex in PC 3 Cells.
    Anticancer Res. 2016;36:1135-42.
    PubMed     Text format     Abstract available


  56. OWEN S, Sanders AJ, Mason MD, Jiang WG, et al
    Targeting of Receptor Activator of Nuclear Kappa B (RANK) in PC-3 Cells Increases Cell Proliferation and Matrix Adhesion In Vitro.
    Anticancer Res. 2016;36:1127-34.
    PubMed     Text format     Abstract available


    February 2016
  57. YENCILEK F, Yilmaz SG, Yildirim A, Gormus U, et al
    Apolipoprotein E Genotypes in Patients with Prostate Cancer.
    Anticancer Res. 2016;36:707-11.
    PubMed     Text format     Abstract available


  58. BURKE AJ, Ali H, O'Connell E, Sullivan FJ, et al
    Sensitivity Profiles of Human Prostate Cancer Cell Lines to an 80 Kinase Inhibitor Panel.
    Anticancer Res. 2016;36:633-41.
    PubMed     Text format     Abstract available


    January 2016
  59. YAMASAKI M, Yuasa T, Yamamoto S, Hayashi T, et al
    Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:361-5.
    PubMed     Text format     Abstract available


  60. CHOI KW, Suh H, Oh HL, Ryou C, et al
    p21CIP1 Induces Apoptosis via Binding to BCL2 in LNCaP Prostate Cancer Cells Treated with MCS-C3, A Novel Carbocyclic Analog of Pyrrolopyrimidine.
    Anticancer Res. 2016;36:213-20.
    PubMed     Text format     Abstract available


  61. RAMACHANDRAN K, Speer C, Nathanson L, Claros M, et al
    Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer.
    Anticancer Res. 2016;36:161-8.
    PubMed     Text format     Abstract available


  62. ELGQVIST J, Timmermand OV, Larsson E, Strand SE, et al
    Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide 177Lu Compared to Alpha Particles and Gamma Rays.
    Anticancer Res. 2016;36:103-9.
    PubMed     Text format     Abstract available


  63. LINDHOLM PF, Hwang YS
    LPA Increases Tumor Growth and Bone Destruction Through Enhancement of Osteoclastogenic Cytokines.
    Anticancer Res. 2016;36:61-70.
    PubMed     Text format     Abstract available


    December 2015
  64. SHIOTA M, Takeuchi A, Sugimoto M, Kashiwagi E, et al
    Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
    Anticancer Res. 2015;35:6925-32.
    PubMed     Text format     Abstract available


  65. SPICK C, Polanec SH, Mitterhauser M, Wadsak W, et al
    Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.
    Anticancer Res. 2015;35:6787-91.
    PubMed     Text format     Abstract available


  66. RAATIKAINEN S, Aaaltomaa S, Karja V, Soini Y, et al
    Increased Peroxiredoxin 6 Expression Predicts Biochemical Recurrence in Prostate Cancer Patients After Radical Prostatectomy.
    Anticancer Res. 2015;35:6465-70.
    PubMed     Text format     Abstract available


    November 2015
  67. MAIER GS, Horas K, Kurth AA, Lazovic D, et al
    Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma.
    Anticancer Res. 2015;35:6281-5.
    PubMed     Text format     Abstract available


    October 2015
  68. AMBROSIO MR, Rocca BJ, Barone A, Ginori A, et al
    Lymphatic Vascularization in Prostate Adenocarcinoma: Correlation with Tumor Grade, Androgen Withdrawal and Prognosis.
    Anticancer Res. 2015;35:5595-600.
    PubMed     Text format     Abstract available


  69. NOLTE E, Sobel A, Wach S, Hertlein H, et al
    The New Semisynthetic Cardenolide Analog 3beta-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines.
    Anticancer Res. 2015;35:5271-5.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: